Anna Elinder Camburn

Supplementary Table S3 from Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia

John Nathan Allan, Ian W. Flinn, Tanya Siddiqi, Paolo Ghia et autres

Representativeness Data

Supplementary Figure S1 from Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia

John Nathan Allan, Ian W. Flinn, Tanya Siddiqi, Paolo Ghia et autres

Supplementary Figure S1. Kaplan-Meier curves of progression-free survival (A) and overall survival (B) in the total pooled population of patients treated with fixed-duration ibrutinib plus venetoclax in the FD cohort and the MRD cohort placebo arm. Tick marks indicate censored patients.

Supplementary Table S1 from Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia

John Nathan Allan, Ian W. Flinn, Tanya Siddiqi, Paolo Ghia et autres

Supplementary Table S1. Patient demographics and disease characteristics at baseline by cohort.

Supplementary Table S2 from Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia

John Nathan Allan, Ian W. Flinn, Tanya Siddiqi, Paolo Ghia et autres

Supplementary Table S2. Sensitivity analysis of outcomes in patients with versus without high-risk features, excluding patients from the CAPTIVATE MRD cohort placebo arm

71 | FINAL ANALYSIS OF FIXED‐DURATION IBRUTINIB + VENETOCLAX FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL) IN THE PHASE 2 CAPTIVATE STUDY

Paolo Ghia, PM Barr, John Nathan Allan, Tanya Siddiqi et autres

it, us, au, nz, es (code pays fourni par la source)

Final analysis of fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in the phase 2 CAPTIVATE study.

Paolo Ghia, Paul M. Barr, John Nathan Allan, Tanya Siddiqi et autres

7036 Background: First-line ibrutinib (Ibr) + venetoclax (Ven) treatment for CLL/SLL was tested in the phase 2 CAPTIVATE study, including minimal residual disease (MRD)–guided randomized discontinuation (MRD cohort) and Fixed Duration (FD) cohorts. We report final analysis results for patients (pts) treated …

it, us, au, nz, es (code pays fourni par la source)

CLL-057 Outcomes in High-Risk Subgroups After Fixed-Duration Ibrutinib (Ibr) + Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Up to 5.5 Years of Follow-Up in the Phase 2 CAPTIVATE Study

William G. Wierda, Ryan W. Jacobs, Paul M. Barr, John Nathan Allan et autres

us, it, au, nz, es (code pays fourni par la source)

Outcomes in High-Risk Subgroups After Fixed-Duration Ibrutinib (Ibr) + Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Up to 5.5 Years of Follow-Up in the Phase 2 CAPTIVATE Study

William G. Wierda, Ryan W. Jacobs, Paul M. Barr, John Nathan Allan et autres

Outcomes in high-risk subgroups after fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Up to 5.5 years of follow-up in the phase 2 CAPTIVATE study.

William G. Wierda, Ryan W. Jacobs, Paul M. Barr, John Nathan Allan et autres

7009 Background: The phase 2 CAPTIVATE study evaluated first-line ibrutinib (Ibr) + venetoclax (Ven) for CLL/SLL in 2 cohorts: minimal residual disease (MRD)-guided randomized discontinuation (MRD cohort) and Fixed Duration (FD cohort). Ibr±Ven retreatment was allowed in patients (pts) who had progressive …

us, it, au, nz, es (code pays fourni par la source)

Supplementary Table S2 from Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia

John Nathan Allan, Ian W. Flinn, Tanya Siddiqi, Paolo Ghia et autres

Supplementary Table S2. Sensitivity analysis of outcomes in patients with versus without high-risk features, excluding patients from the CAPTIVATE MRD cohort placebo arm

Data from Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia

John Nathan Allan, Ian W. Flinn, Tanya Siddiqi, Paolo Ghia et autres

AbstractPurpose: The CAPTIVATE study investigated first-line ibrutinib plus venetoclax for chronic lymphocytic leukemia in 2 cohorts: minimal residual disease (MRD)-guided randomized discontinuation (MRD cohort) and Fixed Duration (FD cohort). We report outcomes of fixed-duration ibrutinib plus venetoclax in patients with high-risk genomic …

us, it, au, nz (code pays fourni par la source)

Supplementary Figure S1 from Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia

John Nathan Allan, Ian W. Flinn, Tanya Siddiqi, Paolo Ghia et autres

Supplementary Figure S1. Kaplan-Meier curves of progression-free survival (A) and overall survival (B) in the total pooled population of patients treated with fixed-duration ibrutinib plus venetoclax in the FD cohort and the MRD cohort placebo arm. Tick marks indicate censored patients.